Inkocell Therapeutics focuses on developing innovative therapies for cancer treatment, leveraging advanced technologies in the field of immuno-oncology. The company is dedicated to creating novel therapeutic agents that harness the body's immune system to target and eliminate cancer cells. Their pipeline includes a range of product candidates that utilize proprietary platforms designed to enhance the efficacy and specificity of cancer therapies, aiming to improve patient outcomes and minimize side effects.

The technologies employed by Inkocell Therapeutics encompass a variety of approaches, including the development of targeted therapies and immune modulators. These technologies are designed to activate and enhance the immune response against tumors, utilizing mechanisms such as antibody-drug conjugates and engineered immune cells. By focusing on the interplay between cancer and the immune system, Inkocell Therapeutics aims to pioneer new treatment modalities that can address unmet medical needs in oncology, ultimately striving to provide more effective and personalized treatment options for patients.

Switzerland

Inkocell Therapeutics has developed an NK-tailored CAR receptor, specifically engineered for NK cells, rather than adapting T-cell designs. This innovation enhances NK-cell activity, creating a powerful new generation of therapies. Inkocell’s approach is off-the-shelf and scalable, lowering costs while broadening access for patients. Inkocell is advancing two lead programs: the first targets B-cell malignancies, while the second aims to overcome resistance in solid tumors. Together, they provide a foundation for future expansion into autoimmune and fibrotic diseases.

Inkocell Therapeutics

Company Details